The Emerging Field of Longevity Medicine
Longevity medicine is rapidly evolving from a fringe concept to a mainstream clinical discipline. Practitioners who incorporate longevity science — from senolytic therapy and NAD+ optimization to cardiovascular risk stratification and methylation age testing — are at the leading edge of preventive medicine. Understanding the core tools and evidence base positions you to serve a growing, highly motivated patient population.
Biological Age vs. Chronological Age
Biological age — the physiological age of your tissues and cells, as opposed to your calendar age — is measurable and modifiable. Tools for assessing biological age include: epigenetic clock testing (GrimAge, PhenoAge via TruDiagnostic or SiO2 Bio), telomere length testing, grip strength and VO2max as functional biomarkers, and advanced metabolic and inflammatory panels. Biological age testing provides both a compelling clinical benchmark and a powerful patient motivator.
NAD+ Optimization
Nicotinamide adenine dinucleotide (NAD+) is a critical coenzyme in cellular energy production and DNA repair. NAD+ levels decline 40–60% between age 20 and 60, contributing to mitochondrial dysfunction, impaired cellular repair, and metabolic decline. IV NAD+ infusions (500–1000mg over 1–4 hours) provide direct cellular replenishment with documented effects on energy, cognition, and recovery. Oral precursors — NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) — raise NAD+ through the salvage pathway and are more practical for long-term use.
Senolytic Therapy
Senescent cells — cells that have stopped dividing but resist apoptosis — accumulate with age and secrete the SASP (senescence-associated secretory phenotype), a cocktail of inflammatory cytokines that accelerates tissue aging and disease. Senolytics selectively clear senescent cells. The most studied protocol is intermittent dasatinib + quercetin (D+Q), shown in multiple studies to reduce senescent cell burden and improve physical function. This remains an emerging area — appropriate patient selection and monitoring are essential.
Cardiovascular Longevity: VO2max as the Single Best Predictor
VO2max — the maximum rate of oxygen consumption during exercise — is the single strongest predictor of all-cause mortality, stronger even than smoking status or blood pressure. The difference between “low” and “elite” VO2max for age represents a 5x difference in mortality risk. Measuring VO2max (via cardiopulmonary exercise testing or validated submaximal protocols) and prescribing zone 2 and high-intensity interval training to improve it is foundational longevity medicine.
Metformin and Rapamycin: The Longevity Drug Conversation
Metformin has compelling longevity evidence beyond its glucose-lowering effects — including AMPK activation, mTORC1 inhibition, and potential cancer-protective effects. The TAME trial (Targeting Aging with Metformin) is ongoing. Rapamycin — an mTOR inhibitor — has produced consistent lifespan extension in multiple animal models and is being used off-label by a small but growing number of longevity clinicians. Understanding the evidence base, dosing considerations, and risk-benefit calculus of these agents is becoming a core competency in longevity medicine.